

Status: This version of this schedule contains provisions that are prospective.

Changes to legislation: There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Advisory Bodies) Regulations 2005. Any changes that have already been made by the team appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

PROSPECTIVE

SCHEDULE 1 **U.K.**

Regulation 8

AMENDMENTS TO THE MEDICINES ACT 1968

1. In section 20 of the Act (grant or refusal of licence)—
 - (a) in subsection (3), omit “or, if for the time being there is no such committee, with the Commission”;
 - (b) omit subsection (4).

Commencement Information

- II** Sch. 1 para. 1 in force at 30.10.2005, see [reg. 1\(1\)](#)

2. For section 21 of the Act (procedure on reference to appropriate committee or Commission), substitute—

“Procedure on reference to appropriate committee

21.—(1) Where the appropriate committee are consulted under section 20(3) of this Act and are of the provisional opinion that, on grounds relating to safety, quality or efficacy, they—

- (a) may be unable to advise the licensing authority to grant the licence; or
- (b) may be unable to advise the licensing authority to grant it unless it contains provisions otherwise than in accordance with the application,

they shall notify the applicant accordingly.

(2) A person who has been so notified may, within the time allowed, give notice of his wish to make written or oral representations to the appropriate committee.

(3) The appropriate committee shall give the applicant an opportunity to make such representations in accordance with subsections (4) to (7) of this section.

(4) Subject to subsection (5) of this section, the applicant shall provide the appropriate committee with—

- (a) his written representations or a written summary of the oral representations he intends to make; and
- (b) any documents on which he wishes to rely in support of those representations,

before the end of the period of six months beginning with the date of the notice referred to in subsection (2) of this section, or within such shorter period as the appropriate committee may specify in the notification under subsection (1).

(5) If the applicant so requests, the appropriate committee may extend the time limit referred to in subsection (4) of this section, up to a maximum period of twelve months beginning with the date of the notice referred to in subsection (2) of this section.

(6) The applicant may not submit any additional written representations or documents once the time limit referred to in subsections (4) and (5) of this section has expired, except with the permission of the appropriate committee.

Status: This version of this schedule contains provisions that are prospective.

Changes to legislation: There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Advisory Bodies) Regulations 2005. Any changes that have already been made by the team appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

(7) If the applicant gave notice of his wish to make oral representations, the appropriate committee shall, after receiving a written summary and any other documents in accordance with subsection (4) of this section, arrange for the applicant to make such representations at a hearing before the committee.

(8) The appropriate committee shall—

- (a) take into account such representations as are made in accordance with this section; and
- (b) report their findings and advice to the licensing authority, together with the reasons for their advice.

(9) After receiving the report of the appropriate committee, the licensing authority shall—

- (a) decide whether to grant or refuse the application, or to grant it otherwise than in accordance with the application; and
- (b) take the report into account when making their decision.

(10) The licensing authority shall notify the applicant of—

- (a) the decision made pursuant to subsection (9) of this section; and
- (b) the advice given to them by the appropriate committee and the reasons for that advice.

(11) If—

- (a) the applicant has made representations in accordance with this section and the licensing authority have notified the applicant of the authority's decision to refuse to grant the licence, or to grant it otherwise than in accordance with the application; or
- (b) the applicant has not made representations in accordance with this section and the licensing authority have notified the applicant of the authority's decision to refuse to grant the licence, or to grant it otherwise than in accordance with the application, on grounds which differ from those relied on in the advice of the appropriate committee,

the applicant may, within the time allowed, notify the licensing authority that he wishes to appear before and be heard by a person appointed by the licensing authority with respect to the decision.

(12) In this Part of the Act, “the time allowed” means the period of twenty-eight days beginning with the date of the relevant notification, or such longer period as the licensing authority may allow in any particular case.”.

Commencement Information

I2 Sch. 1 para. 2 in force at 30.10.2005, see [reg. 1\(1\)](#)

3. For section 22 of the Act (procedure in other cases) substitute the following sections—

“Procedure in other cases

22.—(1) This section applies when—

- (a) an application is made for the grant of a licence under this Part of this Act; and
- (b) the appropriate committee—
 - (i) is not consulted under subsection (3) of section 20, or

Status: This version of this schedule contains provisions that are prospective.

Changes to legislation: There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Advisory Bodies) Regulations 2005. Any changes that have already been made by the team appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

- (ii) is consulted under that subsection but does not give a provisional opinion in accordance with section 21(1).
- (2) If the licensing authority propose—
 - (a) to refuse to grant the licence, or
 - (b) to grant it otherwise than in accordance with the application,they shall notify the applicant of their proposals and the reasons for them.
- (3) If the applicant is so notified, he may, within the time allowed—
 - (a) notify the licensing authority of his wish to appear before and be heard by a person appointed by the licensing authority with respect to the proposal; or
 - (b) make representations in writing to the licensing authority with respect to the proposal referred to in the notification.
- (4) If the applicant makes written representations in accordance with subsection (3)(b) of this section, the licensing authority shall take those representations into account before determining the application.

Hearing before person appointed

- 22A.**—(1) If the applicant gives notice under section 21(11) or section 22(3) of his wish to appear before and be heard by a person appointed by the licensing authority, the authority shall—
- (a) make that appointment; and
 - (b) arrange for the applicant to have an opportunity of appearing before that person.
- (2) The person appointed—
- (a) shall not be, or at any time have been, a member of—
 - (i) the Commission on Human Medicines or any of its Expert Advisory Groups,
 - (ii) the Medicines Commission formerly established under section 2 of this Act or any of its committees, or
 - (iii) a committee established under section 4 of this Act, or any sub-committee of such a committee; and
 - (b) shall not be an officer or servant of any Minister of the Crown.
- (3) Subject to subsection (4) of this section, the applicant shall provide the person appointed with—
- (a) a written summary of the oral representations he intends to make; and
 - (b) any documents on which he wishes to rely in support of those representations,
- before the end of the period of three months beginning with the date of the notice referred to in subsection (1) of this section.
- (4) If the applicant so requests, the person appointed may, after consulting the licensing authority, extend the time limit referred to in subsection (3) of this section, up to a maximum period of six months beginning with the date of the notice referred to in subsection (1) of this section.
- (5) If the applicant fails to comply with the time limit in subsection (3) of this section, or, where he has been granted an extended time limit under subsection (4) of this section, that time limit—
- (a) he may not appear before or be heard by the person appointed, and

Status: This version of this schedule contains provisions that are prospective.

Changes to legislation: There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Advisory Bodies) Regulations 2005. Any changes that have already been made by the team appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

(b) the licensing authority shall decide whether to grant or refuse the licence, or to grant it otherwise than in accordance with the application, and notify the applicant accordingly.

(6) The applicant may not submit any additional written representations or documents once the time limit has expired, except with the permission of the person appointed.

(7) At the hearing before the person appointed, both the applicant and the licensing authority may make representations.

(8) If the applicant so requests the hearing shall be in public.

(9) After the hearing—

(a) the person appointed shall provide a report to the licensing authority; and

(b) the licensing authority shall take the report into account and decide whether to grant or refuse the licence, or to grant it otherwise than in accordance with the application, or to confirm or alter their decision, as the case may be.

(10) The licensing authority shall then—

(a) notify the applicant of their decision;

(b) if the applicant so requests, provide the applicant with a copy of the report of the person appointed.”.

Commencement Information

I3 Sch. 1 para. 3 in force at 30.10.2005, see [reg. 1\(1\)](#)

4. In section 24 (duration and renewal of licence), in subsection (4), for “21 and 22”, substitute “21 to 22A”.

Commencement Information

I4 Sch. 1 para. 4 in force at 30.10.2005, see [reg. 1\(1\)](#)

5. In section 27 (proceedings on application for licence of right)—

(a) in subsection (1), for “22” substitute “22A”; and

(b) for subsection (8), substitute the following subsection—

“Subsections (2), (8) and (10)(b) of section 22A of this Act shall have effect in relation to a person appointed under subsection (3) of this section and to proceedings before him and his report as they have effect for the purposes of that section.”

Commencement Information

I5 Sch. 1 para. 5 in force at 30.10.2005, see [reg. 1\(1\)](#)

6. In section 36 (application for, and issue of, certificate), in subsection (3), for “22” substitute “22A”.

Commencement Information

I6 Sch. 1 para. 6 in force at 30.10.2005, see [reg. 1\(1\)](#)

Status: This version of this schedule contains provisions that are prospective.

Changes to legislation: There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Advisory Bodies) Regulations 2005. Any changes that have already been made by the team appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

7. In section 38 (duration and renewal of certificate)—
- (a) in subsection (5), for “21 and 22” substitute “21 to 22A”; and
 - (b) in subsection (6), for “section 21 or section 22” substitute “section 21, 22 or 22A”.

Commencement Information

I7 Sch. 1 para. 7 in force at 30.10.2005, see [reg. 1\(1\)](#)

8. In section 43 (extension of section 7 to certain special circumstances), in subsection (4), for “22” substitute “22A”.

Commencement Information

I8 Sch. 1 para. 8 in force at 30.10.2005, see [reg. 1\(1\)](#)

9. In section 44 of the Act (provision of information to licensing authority), in subsection (3), omit “by the Commission or” in both places where it occurs.

Commencement Information

I9 Sch. 1 para. 9 in force at 30.10.2005, see [reg. 1\(1\)](#)

10. In section 58 of the Act (medicinal products on prescription only), in subsection (6), omit “, or, if for the time being there is no such committee, shall consult the Commission”.

Commencement Information

I10 Sch. 1 para. 10 in force at 30.10.2005, see [reg. 1\(1\)](#)

11. In section 60 of the Act (restricted sale, supply and administration of certain medicinal products), in subsection (7), omit “, or, if for the time being there is no such committee, shall consult the Commission”.

Commencement Information

I11 Sch. 1 para. 11 in force at 30.10.2005, see [reg. 1\(1\)](#)

- 12.—(1) Section 62 of the Act (prohibition of sale, supply, or importation, of certain medicinal products) shall be amended as follows.

(2) In subsection (3) omit “, or if for the time being there is no such committee, shall consult the Commission”.

(3) In subsection (4) omit “or the Commission”.

(4) In subsection (5), for “Commission” (at each place where it occurs) substitute “appropriate committee”.

(5) For subsection (7) substitute—

“(7) If an order is made under this section and either—

- (a) the appropriate committee have not considered the proposal to make the order, or
- (b) the order is made contrary to the advice of the appropriate committee,

Status: This version of this schedule contains provisions that are prospective.

Changes to legislation: There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Advisory Bodies) Regulations 2005. Any changes that have already been made by the team appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

the order shall include a statement of the fact that it has been so made.”.

Commencement Information

I12 Sch. 1 para. 12 in force at 30.10.2005, see [reg. 1\(1\)](#)

13. In section 65 of the Act (compliance with standards specified in monographs), in subsection (8), for “Medicines Commission” substitute “Commission”.

Commencement Information

I13 Sch. 1 para. 13 in force at 30.10.2005, see [reg. 1\(1\)](#)

14. In section 132 of the Act (general interpretation provisions), in subsection (1)—

(a) before the definition of “analysis”, insert the following definition—

““Advisory Body” has the meaning given to it by paragraph 1 of Schedule 1A to this Act;”,

(b) in the definition of “the Commission”, for “Medicines Commission” substitute “Commission for Human Medicines”;

(c) after the definition of “enforcement authority”, insert the following definition—

““Expert Advisory Group” means an Expert Advisory Group established under paragraph 3 or 4 of Schedule 1A to this Act;”,

(d) after the definition of “herd”, insert the following definition—

““the Homoeopathic Regulations” means the Medicines (Homoeopathic Medicinal Products for Human Use) Regulations 1994(1)

(e) after the definition of “manufacture”, insert the following definition—

““the Marketing Authorisation Regulations” means the Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994;”,

(f) in the definition of “the time allowed”, for “section 21(8)” substitute “section 21(12)”.

Commencement Information

I14 Sch. 1 para. 14 in force at 30.10.2005, see [reg. 1\(1\)](#)

15. For Schedule 2 to the Act (procedure for suspension, revocation or variation of licence), substitute—

“SCHEDULE 2 **U.K.**

Section 29

SUSPENSION, REVOCATION OR VARIATION OF LICENCE

Procedure on consultation with appropriate committee

1. Subject to paragraph 8 below, where the licensing authority propose, in the exercise of their powers under section 28 of this Act—

(1) [S.I. 1994/105](#).

Status: This version of this schedule contains provisions that are prospective.

Changes to legislation: There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Advisory Bodies) Regulations 2005. Any changes that have already been made by the team appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

- (a) to suspend, revoke or vary a product licence on the grounds specified in paragraph (a) or paragraph (c) of subsection (3) of that section, in a case where it appears to the licensing authority that the matters or characteristics in question are such as to affect the safety, efficacy or quality of medicinal products to which the licence relates, or
- (b) to suspend, revoke or vary a product licence on any of the grounds specified in paragraph (g) or paragraph (h) of that subsection,

the licensing authority shall not suspend, revoke or vary the licence except after consultation with the appropriate committee.

2.—(1) Where the appropriate committee are consulted under the preceding paragraph and are of the provisional opinion that, on such grounds as are mentioned in that paragraph, they may have to advise the licensing authority that the product licence ought to be revoked, varied or suspended, the appropriate committee shall notify the holder of the licence accordingly.

(2) A person who has been so notified may, within the time allowed, give notice of his wish to make written or oral representations to the appropriate committee.

(3) The appropriate committee shall give the holder of the licence an opportunity to make such representations in accordance with sub-paragraphs (4) to (7) of this paragraph.

(4) Subject to sub-paragraph (5) of this paragraph, the holder of the licence shall provide the appropriate committee with—

- (a) his written representations or a written summary of the oral representations he intends to make; and
- (b) any documents on which he wishes to rely in support of those representations,

before the end of the period of six months beginning with the date of the notice referred to in sub-paragraph (2) of this paragraph, or within such shorter period as the appropriate committee may specify in the notification under sub-paragraph (1) of this paragraph.

(5) If the holder of the licence so requests, the appropriate committee may extend the time limit referred to in sub-paragraph (4) of this paragraph, up to a maximum period of twelve months beginning with the date of the notice referred to in sub-paragraph (2) of this paragraph.

(6) The holder of the licence may not submit any additional written representations or documents once the time limit referred to in sub-paragraphs (4) and (5) of this paragraph has expired, except with the permission of the appropriate committee.

(7) If the holder gave notice of his wish to make oral representations, the appropriate committee shall, after receiving a written summary and any other documents in accordance with sub-paragraph (4) of this paragraph, arrange for the holder to make such representations at a hearing before the committee.

(8) The appropriate committee shall—

- (a) take into account such representations as are made in accordance with this paragraph; and
- (b) report their findings and advice to the licensing authority, together with the reasons for their advice.

3.—(1) After receiving the report of the appropriate committee the licensing authority shall—

- (a) decide whether to continue with the proposal to revoke, vary or suspend the product licence; and

Status: This version of this schedule contains provisions that are prospective.

Changes to legislation: There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Advisory Bodies) Regulations 2005. Any changes that have already been made by the team appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

(b) take the report into account when making their decision.

(2) The licensing authority shall then notify the holder of the licence of—

- (a) the decision made pursuant to sub-paragraph (1) of this paragraph; and
- (b) the advice given to them by the appropriate committee and the reasons for that advice.

4. If—

- (a) the appropriate committee was consulted under paragraph 1 of this Schedule;
- (b) the committee did not give a provisional opinion under paragraph 2(1) of this Schedule; and
- (c) the licensing authority propose—
 - (i) to determine the matter in a way which differs from the advice of the committee, or
 - (ii) to suspend, revoke or vary the licence on grounds not relating to safety, quality or efficacy,

the authority shall notify the holder of the licence accordingly.

(2) A notification given under sub-paragraph (1) of this paragraph shall state—

- (a) the advice of the committee and the reasons stated by the committee for that advice; and
- (b) the proposals of the licensing authority and the reasons for them.

5.—(1) Subject to sub-paragraph (4) of this paragraph, a person to whom a notification has been given under paragraph 3(2) of this Schedule may, within the time allowed, notify the licensing authority that he wishes to appear before and be heard by a person appointed by the licensing authority with respect to the decision.

(2) A person to whom a notification has been given under paragraph 4(1) of this Schedule may, within the time allowed—

- (a) notify the licensing authority that he wishes to appear before and be heard by a person appointed for the purpose by the licensing authority, or
- (b) make representations in writing to the licensing authority with respect to the proposal referred to in the notification.

(3) If the applicant makes written representations in accordance with sub-paragraph (2) (b) of this paragraph, the licensing authority shall take those representations into account before determining the matter.

(4) Sub-paragraph (1) of this paragraph shall not apply where—

- (a) the person has not made any representations in accordance with paragraph 2(4) to (7) of this Schedule; and
- (b) the decision of the licensing authority was in accordance with the advice of the appropriate committee.

Procedure in other cases

6.—(1) This paragraph applies where the licensing authority propose, in the exercise of the powers conferred by section 28 of this Act—

- (a) to suspend, revoke or vary a licence under Part 2 of this Act, other than a product licence; or

Status: This version of this schedule contains provisions that are prospective.

Changes to legislation: There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Advisory Bodies) Regulations 2005. Any changes that have already been made by the team appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

- (b) to suspend, revoke or vary a product licence where the holder of the licence has been given neither—
 - (i) notice of any provisional opinion or any advice of the appropriate committee which led to that proposal under paragraphs 2 and 3 of this Schedule; nor
 - (ii) notice of that proposal under paragraph 4 of this Schedule,and the provisions of paragraph 8 of this Schedule do not apply.
- (2) The licensing authority shall notify the holder of the licence of—
 - (a) their proposals;
 - (b) the reasons for them; and
 - (c) the date (not being earlier than twenty-eight days from the date of the notification) on which it is proposed that the suspension, revocation or variation should take effect.
- (3) The holder of the licence may, before the date specified in the notification—
 - (a) notify the licensing authority of his wish to appear before and be heard by a person appointed by the licensing authority with respect to the decision; or
 - (b) make representations in writing to the licensing authority with respect to the proposal referred to in the notification.
- (4) If the applicant makes written representations in accordance with sub-paragraph (3) (b) of this paragraph, the licensing authority shall take those representations into account before determining the matter.

Hearing before person appointed

- 7.—(1) If the holder of the licence gives notice under paragraph 5 or 6 of this Schedule of his wish to appear before and be heard by a person appointed by the licensing authority, the authority shall—
- (a) make that appointment; and
 - (b) arrange for the applicant to have an opportunity of appearing before that person.
- (2) The person appointed—
- (a) shall not be, or at any time have been, a member of—
 - (i) the Commission on Human Medicines or any of its Expert Advisory Groups,
 - (ii) the Medicines Commission formerly established under section 2 of this Act or any of its committees, or
 - (iii) a committee established under section 4 of this Act, or any sub-committee of such a committee; and
 - (b) shall not be an officer or servant of any Minister of the Crown.
- (3) Subject to sub-paragraph (4) of this paragraph, the holder of the licence shall provide the person appointed with—
- (a) a written summary of the oral representations he intends to make; and
 - (b) any documents on which he wishes to rely in support of those representations, before the end of the period of three months beginning with the date of the notice referred to in sub-paragraph (1) of this paragraph.

Status: This version of this schedule contains provisions that are prospective.

Changes to legislation: There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Advisory Bodies) Regulations 2005. Any changes that have already been made by the team appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

(4) If the holder of the licence so requests, the person appointed may, after consulting the licensing authority, extend the time limit referred to in sub-paragraph (3) of this paragraph, up to a maximum period of six months beginning with the date of the notice referred to in sub-paragraph (1) of this paragraph.

(5) If the holder of the licence fails to comply with the time limit in sub-paragraph (3) of this paragraph, or, where he has been granted an extended time limit under sub-paragraph (4) of this paragraph, that time limit—

- (a) he may not appear before or be heard by the person appointed, and
- (b) the licensing authority shall decide whether to grant or refuse the licence, or to grant it otherwise than in accordance with the application, and notify the applicant accordingly.

(6) The holder of the licence may not submit any additional written representations or documents once the time limit has expired, except with the permission of the person appointed.

(7) At the hearing before the person appointed, both the holder of the licence and the licensing authority may make representations.

(8) If the holder of the licence so requests the hearing shall be in public.

(9) After the hearing—

- (a) the person appointed shall provide a report to the licensing authority; and
- (b) the licensing authority shall take this report into account and decide whether to revoke, vary or suspend the licence.

(10) The licensing authority shall then—

- (a) notify the holder of the licence of their decision;
- (b) if the holder so requests, provide the holder with a copy of the report of the person appointed.

Procedure in cases of urgency

8. Notwithstanding anything in paragraphs 1 to 7 of this Schedule, where it appears to the licensing authority that in the interests of safety it is necessary to suspend a licence under Part 2 of this Act with immediate effect, the licensing authority may do so, for a period not exceeding three months.

9. If the licence is a product licence, the licensing authority shall report the suspension forthwith to the appropriate committee.

10. If, after the suspension has taken effect—

- (a) it appears to the licensing authority; or
- (b) in the case of a product licence, they are advised by the appropriate committee,

that it is necessary to consider whether the licence ought to be further suspended, or ought to be revoked or varied, the licensing authority (subject to paragraph 11 of this Schedule) shall proceed in accordance with such of the provisions of paragraphs 1 to 7 of this Schedule as are applicable in the circumstances.

11.—(1) This paragraph applies where, in the circumstances specified in paragraph 10 of this Schedule, the licensing authority proceed as mentioned in that paragraph and any proceedings under paragraphs 1 to 7 of this Schedule relating to a further suspension of the licence have not been finally disposed of before the end of the period—

Status: This version of this schedule contains provisions that are prospective.

Changes to legislation: There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Advisory Bodies) Regulations 2005. Any changes that have already been made by the team appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

- (a) for which the licence was suspended under paragraph 8 of this Schedule; or
- (b) for which it has been further suspended under this paragraph.

(2) If it appears to the licensing authority to be necessary in the interests of safety to do so, the authority may further suspend the licence for a period which (in the case of each such further suspension) shall not exceed three months.

(3) The provisions of section 27(7) of this Act shall, with the necessary modifications, have effect for the purpose of determining the date on which any proceedings are taken to be finally disposed of.

Interpretation

12. In this Schedule, the “the time allowed” means the period of twenty-eight days from the date of the relevant notification, or such longer period as the licensing authority may allow in any particular case.”.

Commencement Information

115 Sch. 1 para. 15 in force at 30.10.2005, see [reg. 1\(1\)](#)

Status:

This version of this schedule contains provisions that are prospective.

Changes to legislation:

There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Advisory Bodies) Regulations 2005. Any changes that have already been made by the team appear in the content and are referenced with annotations.

[View outstanding changes](#)

Changes and effects yet to be applied to :

- Sch. 1 para. 1 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 2 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 3 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 4 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 5 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 6 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 7 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 8 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 9 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 10 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 11 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 12 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 13 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 14 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 15 coming into force by [S.I. 2005/1094 reg. 1\(1\)](#)
- Sch. 1 para. 1-11 revoked by [S.I. 2012/1916 Sch. 35](#)
- Sch. 1 para. 12(2)(3) revoked by [S.I. 2012/1916 Sch. 35](#)
- Sch. 1 para. 13-15 revoked by [S.I. 2012/1916 Sch. 35](#)